Tumor-Associated Neolacto-series Antigen Production Service

Tumor-Associated Neolacto-series Antigen Production Service at CD BioGlyco

CD BioGlyco has been dedicated to the Development of Carbohydrate-based Vaccines for many years and has established an advanced Glyco™ Vaccine Development Platform to offer our clients a comprehensive range of Tumor-Associated Carbohydrate Vaccine Development. This includes our specialized tumor-associated neolacto-series antigen production services:

We also offer follow-up antitumor vaccine development services to assist you in accelerating your research process, providing you with additional resources and support to ensure that your vaccine development makes the greatest possible progress.

Applications

• In the field of drug development, neolacto-series antigen plays a crucial role in facilitating the identification and validation of novel drug targets.
• Neolacto-series antigens can be used in immunological studies to help researchers understand the functions and regulatory mechanisms of the immune system.
• The neolacto-series antigens can be used during vaccine development to help promote the immune response of the immune system to specific pathogens.

Fig.1 The heterogeneous expression of (neo-) lacto series glycosphingolipids on normal and cancer cell lines. (Alam, et al., 2017)

Frequently Asked Questions

• What is the structure of neolacto-series Antigen?

Neolacto-series antigen refers to a specific type of sugar molecule, which is a sugar chain structure formed by the addition of different sugar groups to a lactose base. Neolacto-series antigens can form several different variants through different combinations of sugar groups, including the most common one, Galβ1-4(Fucα1-3) GlcNAc, but also other tumor- and immune-related antigens.

• What are the advantages of neolacto-series antigen production services at CD BioGlyco?

CD BioGlyco has advanced technologies and a team focused on glycochemistry, immunology, and vaccine development to provide clients with efficient, reliable, and customized neolacto-series antigen production services. We are committed to ensuring the quality and consistency of our products and focus on the needs and specific requirements of each client.

As a leading global provider of glycolipid antigen manufacturing services, CD BioGlyco specializes in tumor-associated neo-lactone series antigen production services. Our experienced R&D scientists provide you with customized services according to your requirements. Please feel free to contact us if you have any questions regarding our services.

Reference

1. Alam, S.; et al. Altered (neo-) lacto series glycolipid biosynthesis impairs α2-6 sialylation on N-glycoproteins in ovarian cancer cells. Scientific reports. 2017, 7(1): 45367.